Production, characterization, and functional analysis of newly established CD99 monoclonal antibodies MT99/1 and MT99/2

Hybridoma

Volumn 26, Issue 4, 2007, Pages 241-249

  Khunkaewla, Panida ^a   Chiampanichayakul, Sawitree ^a   Yasamut, Umpa ^a   Pata, Supansa ^a   Kasinrerk, Watchara ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD99 ANTIGEN; EPITOPE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD99; MONOCLONAL ANTIBODY MT99/1; MONOCLONAL ANTIBODY MT99/2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BIOTINYLATION; CELL ADHESION; CELL AGGREGATION; CELL LYSATE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL ADHESION MOLECULES; CELL LINE; FEMALE; FLOW CYTOMETRY; HUMANS; JURKAT CELLS; MICE; MICE, INBRED BALB C;

EID: 34548223134     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2007.0504     Document Type: Article

References (43)

1. Ambros IM, et al: MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;67:1886-1893.
2. Gelin C, et al: The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. Embol J 1989;8:3253-3259.
3. Bernard A, et al: A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes. J Immunol 1988;140:1802-1807.
4. Dworzak MN, et al: CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br J Haematol 1999;105:690-695.
5. Kovar H, et al: Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990; 5:1067-1070.
6. Hahn JH, et al: CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997;159:2250-2258.
7. Alberti I, et al: CD99 isoforms expression dictates T cell functional outcomes. Faseb J 2002;16:1946-1948.
8. Lee EJ, et al: CD99 type II is a determining factor for the differentiation of primitive neuroectodermal cells. Exp Mol Med 2003;35:438-447.
9. Jung KC, et al: The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat. FEBS Lett 2003;554: 478-484.
10. Cerisano V, et al: Molecular mechanisms of CD99-induced caspase independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 2004;23:5664-5674.
11. Schenkel AR, et al: CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3:143-150.
12. Bixel G, et al: Mouse CD99 participates in T-cell recruitment into inflamed skin.Blood 2004;104:3205-3213.
13. Lou O, et al: CD99 is a key mediator of the transendothelial migration of neutrophils. J Immunol 2007;178:1136-1143.
14. Imbert AM, et al: CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration. Blood 2006;108:2578-2586.
15. Gil MC, et al: Characterization and epitope mapping of two monoclonal antibodies against human CD99. Exp Mol Med 2002;34: 411-418.
16. Kasinrerk W, et al: CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway. Immunol Lett 2000;71:33-41.
17. Scotlandi K, et al: Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur J Cancer 2006; 42:91-96.
18. Mhawech-Fauceglia P, et al: Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI-1 polyclonal antibodies. Histopathology 2006;49:569-575.
19. Scotlandi K, et al: CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000;60:5134-5142.
20. Dorfman DM, et al: CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis. Mod Pathol 1997;10:283-288.
21. Sohn HW, et al: Engagement of CD99 induces apoptosis through a calcineurin independent pathway in Ewing's sarcoma cells. Am J Pathol 1998;153:1937-1945.
22. Chiampanichayakul S, et al: CD147 contains different bioactive epitopes involving the regulation of cell adhesion and lymphocyte activation. Immunobiology 2006;211:167-178.
23. Kasinrerk W, Tokrasinwit N, and Naveewongpanit P: Production of monoclonal antibody to CD4 antigen and development of reagent for CD4+lymphocyte enumeration. J Med Assoc Thai 1998; 81:879-892.
24. Aruffo A, and Seed B: Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 1987;84:8573-8577.
25. Bernard G, et al: The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes. J Immunol 1995;154:26-32.
26. Bernard G, et al: Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997;158:2543-2550.
27. Kim MK, et al: MHC class II engagement inhibits CD99-induced apoptosis and up-regulation of T cell receptor and MHC molecules in human thymocytes and T cell line. FEBS Lett 2003;546: 379-384.
28. Pettersen RD, et al: CD99 signals caspase-independent T cell death. J Immunol 2001;166:4931-4942.
29. Goodfellow PN, and Tippett P: A human quantitative polymorphism related to Xg blood groups. Nature 1981;289:404-405.
30. Bernard A, et al: A novel human leukocyte differentiation antigen: monoclonal antibody anti-D44 defines a 28 Kd molecule present on immature hematologic cells and a subpopulation of mature T cells. J Immunol 1984;132:2338-2344.
31. Latron F, Blanchard D, and Cartron JP: Immunochemical characterization of the human blood cell membrane glycoprotein recognized by the monoclonal antibody 12E7. Biochem J 1987;247: 757-764.
32. Petty AC, and Tippett P: Investigation of the biochemical relationship between the blood group antigens Xga and CD99 (12E7 antigen) on red cells. Vox Sang 1995; 69:231-235.
33. Byun H.J, et al: A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem 2006;281:34833-34847.
34. Schlossman SF: Leucocyte typing V: white cell differentiation antigens. Proceedings of the Fifth International Workshop and Conference Held in Boston, MA, November 1993. Oxford University Press, Oxford, 1995, p. 2044.
35. Bernard G, et al: CD99 (E2) up-regulates alpha4beta1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol 2000;30:3061-3065.
36. Ostberg JR, Barth RK, and Frelinger JG: The Roman god Janus: a paradigm for the function of CD43. Immunol Today 1998;19: 546-550.
37. Sanchez-Mateos P, et al: Regulatory role of CD43 leukosialin on integrin mediated T-cell adhesion to endothelial and extracellular matrix ligands and its polar redistribution to a cellular uropod. Blood 1995;86:2228-2239.
38. Hahn MJ, et al: Differential activation of MAP kinase family members triggered by CD99 engagement. FEBS Lett 2000;470:350-354.
39. Dransfield I, et al: Divalent cation regulation of the function of the leukocyte integrin LFA-1. J Cell Biol 1992;116:219-226.
40. Leitinger B, et al: The regulation of integrin function by Ca(2+). Biochim Biophys Acta 2000;1498:91-98.
41. Lockshin RA, and Zakeri Z: Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol 2001;2:545-550.
42. Assuncao Guimaraes C, and Linden R: Programmed cell deaths. Apoptosis and alternative death styles. Eur J Biochem 2004;271: 1638-1650.
43. Nagy ZA, and Mooney NA: A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules. J Mol Med 2003;81:757-765.